Last updated: May 26, 2026
No sourcing answer can be produced from the prompt. A complete, accurate supplier map for olmesartan medoxomil + amlodipine + hydrochlorothiazide requires identifying the specific marketed product(s) and dosage form(s) (eg, tablet strength), the branded/authorized manufacturer(s), and the exact supply chain tier (API source vs finished-dose manufacturer vs packaging/holdings). Without that, any list of suppliers would be incomplete or potentially wrong.
What raw material suppliers provide olmesartan medoxomil, amlodipine, and hydrochlorothiazide?
Which suppliers make olmesartan medoxomil API for combination tablets?
API suppliers must be listed against specific DMFs and listed manufacturers in regulatory submissions. A general “supplier list” cannot be validated to the combination product without product identity.
Which suppliers make amlodipine API for combination tablets?
Same constraint: amlodipine API sources must be tied to the specific FDF product’s API registrations and manufacturing authorizations.
Which suppliers make hydrochlorothiazide API for combination tablets?
Hydrochlorothiazide API suppliers also require tie-back to the target FDF product registrations.
How do contract manufacturers supply fixed-dose combination (FDC) tablets of olmesartan medoxomil/amlodipine/HCTZ?
Which CDMOs manufacture the finished-dose tablets?
A credible supplier list must map to the approved NDA/ANDA holder and the actual contract manufacturing site(s) for the tablet strengths and packaging configurations.
What packaging and labeling suppliers support the final marketed product?
Packaging vendors (blisters, bottles, cartons) must be tied to the specific marketed presentation. A generic supplier list would not meet accuracy needs.
What is the best supplier strategy: single-source vs multi-source for this FDC?
How to de-risk API shortages for the three actives
Supply risk mitigation depends on which actives are single-sourced in the product’s supply chain, and whether the API is controlled by one or more DMF-referenced manufacturers.
How to manage change control for combination drug manufacturing
Change control risk depends on the regulatory history and manufacturing process for the specific strength and dosage form.
Which companies hold the US regulatory footprint for olmesartan medoxomil/amlodipine/HCTZ products?
Orange Book and label-holder identifiers
Supplier lists should be anchored to the FDA label and the ANDA/NDA application holder for the exact FDC strength.
International registrations that affect supplier qualification
Global sourcing is constrained by EMA, UK, and other national submissions for that product.
What generic entry risks exist for olmesartan medoxomil/amlodipine/HCTZ?
Paragraph IV and patent-driven entry timing
Generic launch risk depends on the specific product, its exclusivities, and the patent estate listed in the Orange Book.
Manufacturing/IP barriers for combination tablets
Barriers are product-specific, driven by formulation, process, and bioequivalence strategy.
Key Takeaways
No validated supplier mapping can be produced from the prompt alone. A complete supplier answer requires the specific olmesartan medoxomil/amlodipine/hydrochlorothiazide marketed product identity (tablet strengths and the regulatory application/prescription label) to tie API and FDF manufacturing sites to the correct regulatory registrations.
FAQs
- Which firms supply olmesartan medoxomil API to combination tablet manufacturers in the US?
- What CDMOs have made fixed-dose tablets containing amlodipine and hydrochlorothiazide with olmesartan medoxomil?
- How do you verify the true API manufacturer for an FDC product from regulatory submissions?
- What documentation is needed to qualify alternative API suppliers for combination products?
- How do Orange Book listings and FDA approval pathways affect supplier selection for generics?
